MoonLake Immunotherapeutics’ (MLTX) Neutral Rating Reiterated at The Goldman Sachs Group

The Goldman Sachs Group reiterated their neutral rating on shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) in a research note released on Wednesday morning. The Goldman Sachs Group currently has a $7.00 price objective on the stock.

Other equities research analysts have also recently issued reports about the stock. Rothschild & Co Redburn initiated coverage on shares of MoonLake Immunotherapeutics in a research report on Monday, July 28th. They set a “neutral” rating and a $65.00 price target for the company. Stifel Nicolaus cut shares of MoonLake Immunotherapeutics from a “buy” rating to a “hold” rating and set a $13.00 price target for the company. in a research report on Monday, September 29th. Citigroup cut shares of MoonLake Immunotherapeutics from a “buy” rating to a “neutral” rating in a research report on Tuesday. Jefferies Financial Group cut shares of MoonLake Immunotherapeutics from a “buy” rating to a “hold” rating and set a $8.00 price objective for the company. in a report on Monday, September 29th. Finally, Redburn Atlantic upgraded shares of MoonLake Immunotherapeutics to a “hold” rating in a report on Monday, July 28th. Three analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, MoonLake Immunotherapeutics has an average rating of “Hold” and a consensus price target of $37.00.

MoonLake Immunotherapeutics Price Performance

Shares of MLTX opened at $8.43 on Wednesday. MoonLake Immunotherapeutics has a 1-year low of $5.95 and a 1-year high of $62.75. The stock has a market cap of $541.46 million, a PE ratio of -3.03 and a beta of 1.10. The firm has a 50-day simple moving average of $49.95 and a two-hundred day simple moving average of $45.05. The company has a debt-to-equity ratio of 0.21, a current ratio of 16.65 and a quick ratio of 16.65.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.14). During the same quarter last year, the business posted ($0.39) EPS. As a group, analysts forecast that MoonLake Immunotherapeutics will post -1.79 EPS for the current year.

Insider Transactions at MoonLake Immunotherapeutics

In related news, major shareholder Bihua Chen sold 6,494,151 shares of MoonLake Immunotherapeutics stock in a transaction on Monday, September 29th. The stock was sold at an average price of $7.21, for a total value of $46,822,828.71. Following the completion of the transaction, the insider directly owned 2,000,000 shares in the company, valued at approximately $14,420,000. This trade represents a 76.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 12.02% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Deutsche Bank AG grew its holdings in MoonLake Immunotherapeutics by 59.8% during the 4th quarter. Deutsche Bank AG now owns 903 shares of the company’s stock worth $49,000 after acquiring an additional 338 shares in the last quarter. Elevation Point Wealth Partners LLC acquired a new position in MoonLake Immunotherapeutics during the 2nd quarter worth approximately $74,000. US Bancorp DE grew its holdings in MoonLake Immunotherapeutics by 114.4% during the 1st quarter. US Bancorp DE now owns 2,208 shares of the company’s stock worth $86,000 after acquiring an additional 1,178 shares in the last quarter. Quarry LP acquired a new position in MoonLake Immunotherapeutics during the 1st quarter worth approximately $94,000. Finally, Advisors Asset Management Inc. grew its holdings in MoonLake Immunotherapeutics by 81.7% during the 1st quarter. Advisors Asset Management Inc. now owns 4,009 shares of the company’s stock worth $157,000 after acquiring an additional 1,803 shares in the last quarter. Institutional investors and hedge funds own 93.85% of the company’s stock.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.